Source-grounded facts extracted from Sagimet Biosciences Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tim Walbert resigned as Board Member at Sagimet Biosciences Inc..
“On June 12, 2026, Tim Walbert, a member of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), tendered his resignation from the Board, effective as of June 12, 2026.”
Sagimet Biosciences Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2026-06-12 meeting.
“Proposal 2 - Ratification of Independent Registered Public Accountant . The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 19,091,619 13,960 35,224 0”
Sagimet Biosciences Inc. shareholders approved Election of Class III Directors at the 2026-06-12 meeting.
“Each of Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. were elected to the Board to serve as Class III directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Jennifer Jarrett 6,461,429 2,555,268 10,124,106 Anne Phillips, M.D. 7,806,504 1,210,193 10,124,106 David Happel 8,753,884 262,813 10,124,106 George Kemble, Ph.D. 8,688,684 328,013 10,124,106”
Sagimet Biosciences Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026, was $10.7 million.
“Sagimet Biosciences Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Sagimet Biosciences Inc. entered into Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters valued at $164.5 million (effective 2026-04-27).
“On April 27, 2026, Sagimet Biosciences Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “ Underwriters ”) relating to an underwritten offering (the “ Offering ”) of 29,166,700 shares (the “ Shares ”) of the Company’s Series A common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $6.00 per share.”
Sagimet Biosciences Inc. reported preliminary financial results for the Company’s fiscal quarter ended March 31, 2026.
“Sagimet Biosciences, Inc. (the “ Company ”) is furnishing with this Current Report on Form 8-K (the “Current Report”) certain unaudited preliminary financial information for the Company’s fiscal quarter ended March 31, 2026.”
Sagimet Biosciences Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 11, 2026, Sagimet Biosciences Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”
Sagimet Biosciences Inc. engaged KPMG LLP as its auditor.
“i) the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and related interim periods and, concurrently, (ii) the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective immediately. The audit reports of Deloitte on the Company’s financial statements as of December 31, 2024 and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles. Furthermore, during the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and the subsequent interim period through August 18, 2025, there were no disagreements with Deloitte on any matter of accounting principles or practices, financial statement disclosure, or a”
Sagimet Biosciences Inc. dismissed Deloitte & Touche LLP as its auditor.
“iscal year ending December 31, 2025 and related interim periods and, concurrently, (ii) the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective immediately.”
Merdad Parsey departed as Director at Sagimet Biosciences Inc..
“On April 29, 2025 Merdad Parsey, M.D., Ph.D., current member of the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), notified the Board that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), currently scheduled to be held on June 9, 2025.”
Dr. Anne Phillips was appointed as Director at Sagimet Biosciences Inc..
“the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) approved the expansion of the Board from seven directors to nine directors and the appointment of each of Jennifer Jarrett and Dr. Anne Phillips to serve as directors of the Board, in each case, effective as of August 1, 2024”
Jennifer Jarrett was appointed as Director at Sagimet Biosciences Inc..
“the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) approved the expansion of the Board from seven directors to nine directors and the appointment of each of Jennifer Jarrett and Dr. Anne Phillips to serve as directors of the Board, in each case, effective as of August 1, 2024”
Sagimet Biosciences Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter ended March 31, 2024 was $6.6 million compared to a net loss of $6.6 million for the firs.
“today reported financial results for the quarter ended March 31, 2024”
Joseph Oriti resigned as interim Principal Financial Officer and interim Principal Accounting Officer at Sagimet Biosciences Inc..
“On May 5, 2024, Joseph Oriti, the Company’s interim Principal Financial Officer and interim Principal Accounting Officer resigned in connection with Mr. Chauche’s appointment.”
Thierry Chauche was appointed as Chief Financial Officer at Sagimet Biosciences Inc..
“On May 3, 2024, the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) appointed Thierry Chauche as the Company’s Chief Financial Officer, effective May 6, 2024.”
Sagimet Biosciences Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $2.0 million.
“offering, are expected to fund operations for at least the next 12 months based on management’s current operating plan. · Revenues for the year ended December 31, 2023 were $2.0 million compared to no revenues for fiscal 2022. The increase was due to a $2.0 million milestone payment that was recognized in July 2023. · Research and development (R&D) expense for”
Paul Hoelscher was appointed as Director at Sagimet Biosciences Inc..
“the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024”
Tim Walbert was appointed as Director at Sagimet Biosciences Inc..
“the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024”
Joseph Oriti was appointed as Interim Principal Financial Officer and Interim Principal Accounting Officer at Sagimet Biosciences Inc..
“On January 31, 2024, the board of directors (the “ Board ”) of the Company appointed Joseph Oriti as Interim Principal Financial Officer and Interim Principal Accounting Officer, effective as of February 1, 2024 (the “ Effective Date ”).”
Anthony Rimac resigned as Chief Financial Officer at Sagimet Biosciences Inc..
“On December 28, 2023, Anthony Rimac, the Chief Financial Officer of Sagimet Biosciences Inc. (the “ Company ”) provided notice of his intent to resign effective January 31, 2024.”
Joe Oriti was appointed as Interim Principal Financial Officer at Sagimet Biosciences Inc..
“the Company intends to appoint Mr. Oriti as Interim Principal Financial Officer of the Company following Mr. Rimac’s departure”
Gaeton Biscardi was appointed as Interim VP of Finance at Sagimet Biosciences Inc..
“Gaeton Biscardi, Managing Director of Stout, will be serving as the Company’s Interim VP of Finance during this transition period”
Anthony Rimac resigned as Chief Financial Officer at Sagimet Biosciences Inc..
“Anthony Rimac provided notice of his intent to step down as the Chief Financial Officer of Sagimet Biosciences Inc. (the “ Company ”) effective January 31, 2024.”
Sagimet Biosciences Inc. reported the third quarter ended September 30, 2023 results: revenue Revenues for the third quarter ended September 30, 2023 were $2.0 million, net income Net loss for the third quarter ended September 30, 2023 was $6.4 million.
“On November 13, 2023, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.”
Sagimet Biosciences Inc. reported the six months ended June 30, 2023 results: net income The net loss for the six months ended June 30, 2023 totaled $13.4 million.
“The net loss for the six months ended June 30, 2023 totaled $13.4 million compared to $15.8 million for the same period in 2022.”
Sagimet Biosciences Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $6.8 million.
“Net loss for the second quarter ended June 30, 2023 was $6.8 million compared to a net loss of $7.1 million for the second quarter of 2022.”
Anthony Rimac was appointed as Chief Financial Officer, principal financial officer and principal accounting officer at Sagimet Biosciences Inc..
“On July 21, 2023, the Board of Directors (the “ Board ”) of Sagimet Biosciences Inc. (the “ Company ”) appointed Anthony Rimac to Chief Financial Officer, principal financial officer and principal accounting officer of the Company to be effective August 1, 2023.”
Sagimet Biosciences Inc.: Second amended and restated bylaws became effective upon closing of IPO, eliminating stockholder action by written consent, establishing stockholder proposal and director nomination procedures, and conforming to amended charter (effective 2023-07-18).
“on July 18, 2023 in connection with the closing of the IPO, the second amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders to become effective upon the closing of the IPO, became effective.”
Sagimet Biosciences Inc.: Filed eleventh amended and restated certificate of incorporation effective upon closing of IPO, reclassifying common stock, authorizing new classes of common and preferred stock, and eliminating references to previous preferred series (effective 2023-07-18).
“on July 18, 2023 and in connection with the closing of the initial public offering of the Company’s Series A common stock (the “IPO”), the Company filed an eleventh amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.